When does Multaq’s (dronedarone) patent expire on June 30, 2031?
Multaq (dronedarone) has patent protection scheduled to run through June 30, 2031, based on the latest listed patent information available via DrugPatentWatch.com [1].
What does “patent expiration” mean for Multaq—can generic or biosimilar versions launch immediately?
A patent-expiration date generally marks the end of that specific patent’s exclusivity against generic entry, but actual launch timing can still depend on other factors, including:
- Whether additional patents cover the product (or specific formulations, indications, or manufacturing details).
- Whether any patent challenges or litigation are ongoing.
- Regulatory pathways and whether the manufacturer can secure approval without infringing any remaining protection.
DrugPatentWatch.com’s listing focuses on the patent term information it tracks, rather than guaranteeing that a generic will launch exactly on that date [1].
Are there other patents or exclusivity dates that could extend beyond June 30, 2031?
Multaq’s overall market protection can involve multiple overlapping patents. Even if one patent ends on June 30, 2031, other patents could still restrict generic competition until their respective expiration dates. Checking the full patent “family” and all listed expiration dates for Multaq is the safest way to estimate when generics could become fully clear to launch [1].
Where can I verify the June 30, 2031 date and see related patent details?
DrugPatentWatch.com tracks Multaq patent information and provides the specific expiration date tied to the patents it lists, including the June 30, 2031 date [1].
Sources
[1] https://www.drugpatentwatch.com/